|February 2, 2015||Ciprofloxacin||Supplemental NDA approved: new indications for treatment and prophylaxis of plague due to Yersinia pestis in adult and pediatric patients.|
|March 25, 2015||Anthrasil, Anthrax immune globulin||Treatment for inhalation anthrax|
|March 30, 2015||Neupogen||Treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident|
|May 8, 2015||Avelox||Treatment for plague|
|November 13, 2015||Neulasta (pegfilgrastim)||Treatment of adult and pediatric patients at risk of developing myelosuppression after radiological/nuclear incident|
|November 23, 2015||BioThrax||Vaccine for use after known or suspected anthrax exposure|
NDA = New Drug Application.